Genitourinary Oncology Advancement Update from ASCO 2024
At the recent 2024 ASCO annual meeting, Dr. Monica Chatwal, a medical oncologist in the Genitourinary Oncology Department at Moffitt Cancer Center, shared some of the exciting treatments for genitourinary cancers including advancements in Tumor-Infiltrating Lymphocyte (TIL) therapy, Anti-Drug Conjugates (ADCs), oncolytic virus, radiopharmaceuticals and more.
How Moffitt is Impacting Research and Treatment of Genitourinary Cancers
Below are some of the clinical trial breakthroughs.
Clinical Trial 22003 - Prostate Cancer
A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog
Clinical Trial 21460 - Bladder Cancer
Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations
Clinical Trial 21894 - Bladder Cancer
Phase 1 Clinical Trial of lntravesical Adoptive Cell Therapy {ACT) with Tumor Infiltrating Lymphocytes (TIL) for Patients with BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer {NMIBC)
Clinical Trial 21690 Bladder Cancer - Phase 1b
Single Arm Study of CG0070 after Transurethral Resection in Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Our Genitourinary Oncology Department is truly on the leading edge. In addition to spearheading groundbreaking cancer research, we have assembled a multidisciplinary team that is nationally recognized for expertise in urologic malignancies.
Our integrated approach combines the latest research insights with advanced treatment modalities and supportive care services. As a referring colleague, you can trust that your patients will receive the full continuum of compassionate, evidence-based care from our nationally renowned cancer experts.
To refer a patient with a genitourinary cancer or a suspicious tumor finding, please complete our online form or contact a physician liaison for assistance. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.